Study shows risk for emergently treated hypocalcemia with denosumab rises with CKD stage

For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with worsening CKD stage, according to a study published online Nov. 19 in the Annals of Internal Medicine.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup